Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intravenous iclaprim vs intravenous linezolid in complicated skin and skin structure infections
2005-003630-18Phase 3Completed
- Sponsor
- Arpida Ltd
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Iclaprim in Complicated skin and skin structure infection (cSSSI), Staphylococcus aureus infection, beta-hemolytic streptococcal infection and 4 more (2 arms), sponsored by Arpida Ltd. Primary endpoint: Clinical cure rate at test-of-cure visit. Started Dec 2005; status: completed.
02
Drugs
Iclaprim
03
Conditions
Complicated skin and skin structure infection (cSSSI)Staphylococcus aureus infectionbeta-hemolytic streptococcal infectionStreptococcus pyogenes infectionStreptococcus agalactiae infection (GBS)
Beyond the preview
Go deeper on 2005-003630-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003630-18.